Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Do‐Youn Oh(Seoul National University Hospital), Aiwu Ruth He(Georgetown University Medical Center), Mohamed Bouattour(Hôpital Beaujon), Takuji Okusaka(Tokyo National Hospital), Shukui Qin(Jiangsu Cancer Hospital), Li‐Tzong Chen(Kaohsiung Medical University), Masayuki Kitano(Wakayama Medical University), Choong‐kun Lee(Yonsei University), Jin Won Kim(Seoul National University Bundang Hospital), Ming‐Huang Chen(Taipei Veterans General Hospital), Thatthan Suksombooncharoen(Chiang Mai University), Masafumi Ikeda(National Cancer Center Hospital East), Myung Ah Lee(Catholic University of Korea), Jen‐Shi Chen(Linkou Chang Gung Memorial Hospital), Piotr Potemski(Medical University of Lodz), Howard A. Burris(Sarah Cannon), Vikas Ostwal(Homi Bhabha National Institute), Suebpong Tanasanvimon(King Chulalongkorn Memorial Hospital), Chigusa Morizane(Tokyo National Hospital), Renata Zaucha(Gdańsk Medical University), Mairéad G. McNamara(University of Manchester), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Juan E Cundom(Instituto de Diagnóstico e Investigaciones Metabólicas), В. В. Бредер, Benjamin Tan(Washington University in St. Louis), Satoshi Shimizu(Saitama Cancer Center), David Tougeron(Université de Poitiers), Ludovic Evesque(Centre Antoine Lacassagne), Mila Petrova, David B. Zhen(Fred Hutch Cancer Center), Roopinder Gillmore(University College London), Vineet Gupta(Artemis Hospitals), Farshid Dayyani(University of California, Irvine), Joon Oh Park(Samsung Medical Center), Gary L. Buchschacher(Kaiser Permanente), Felipe Rey(Dirección de Investigación y Desarrollo), Hyosung Kim(AstraZeneca (Japan)), Julie Wang(AstraZeneca (United States)), Claire Morgan(AstraZeneca (United States)), Nana Rokutanda(AstraZeneca (United States)), Magdalena Żotkiewicz(AstraZeneca (Poland)), Arndt Vogel(University Health Network), Juan W. Valle(Cholangiocarcinoma Foundation)
Cited by 240Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis